Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nanos homolog 2 (NANOS2) is an evolutionarily conserved RNA-binding protein required for proper development and maintenance of germ cells, especially in the male germline[1][2][3][5]. It features a unique C2HC-type zinc finger domain structure critical for recognizing and binding specific sequences in the 3′ untranslated region (UTR) of target mRNAs, primarily in spermatogonial stem cells[1][5]. NANOS2 exerts its function mainly by recruiting the CCR4-NOT deadenylation complex to facilitate mRNA deadenylation and degradation, thereby repressing the translation of factors that drive spermatogonial stem cell differentiation and female germ cell fate[2][3][5]. Localization studies show that NANOS2 directs this activity to cytoplasmic P-bodies, the principal sites of mRNA decay. Loss of NANOS2 function results in loss of male germ cells and inappropriate meiosis, linking it to infertility and gonadal dysgenesis. Currently, there are no clinically approved drugs targeting NANOS2, nor are there established mechanisms of action or biomarkers for its inhibition or modulation in therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nanos homolog 2 (NANOS2).